Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Immunophenotypic changes induced by menin inhibition in AML

Sanam Loghavi • 14 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia Revumenib

Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the immunophenotypic changes observed in a substantial proportion of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) receiving the menin inhibitor revumenib. Dr Loghavi highlights the importance of being aware of this phenotypic shift as it may interfere with measurable residual disease (MRD) detection by flow cytometry. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sanam Loghavi

1:13
Cytometry versus morphology in the monitoring of AML
Sanam Loghavi • 14 Jun 2024
9:41
The i4MDS consortium and immune monitoring in MDS
Sanam Loghavi et al. • 13 Jun 2024
1:04
Optical genome mapping to detect abnormalities in AML
Sanam Loghavi • 14 Jun 2024
1:46
Challenges in utilizing mutation testing in AML
Sanam Loghavi • 14 Jun 2024

Related Videos

1:59
Phase I study of pevonedistat, azacitidine, and venetoclax in patients with R/R AML
Guru Subramanian Guru Murthy • 11 Jul 2024
1:53
Advancements in prolonging remission post-transplant
Guru Subramanian Guru Murthy • 11 Jul 2024
7:16
Developing a mouse model to elucidate the molecular mechanisms of Richter's transformation
Prajish Iyer • 24 Jul 2024
2:30
Should patients with certain ALL subtypes be considered for alloSCT irrespective of MRD status?
Nicolas Boissel • 15 Jun 2024
The content of VJHemOnc is intended for healthcare professionals